CTI Biopharma logo

CTIC - CTI Biopharma Share Price

$3.04 -0.0  -0.3%

Last Trade - 24/09/21

Small Cap
Market Cap £207.5m
Enterprise Value £156.6m
Revenue £n/a
Position in Universe 4450th / 7170
Unlock CTIC Revenue
Relative Strength (%)
1m +13.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -26.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
16.1 57.4 25.1 26.3 3.35 0.000 13.6 62.5 -100.0%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2021, CTI BioPharmaCorp revenues was not reported. Net loss increased 41% to$36.9M. Higher net loss reflects Other selling , generalincrease from $6.1M to $15.9M (expense), Research anddevelopment increase of 98% to $18.7M (expense), Interestincome decrease of 88% to $19K (income). Basic Earnings perShare excluding Extraordinary Items decreased from -$0.39to -$0.44.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CTIC Revenue Unlock CTIC Revenue

Net Income

CTIC Net Income Unlock CTIC Revenue

Normalised EPS

CTIC Normalised EPS Unlock CTIC Revenue

PE Ratio Range

CTIC PE Ratio Range Unlock CTIC Revenue

Dividend Yield Range

CTIC Dividend Yield Range Unlock CTIC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CTIC EPS Forecasts Unlock CTIC Revenue
Profile Summary

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated December 14, 2017
Public Since September 26, 2017
No. of Shareholders: 109
No. of Employees: 22
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 93,309,923
Free Float (0.0%)
Eligible for
CTIC Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CTIC
Upcoming Events for CTIC
Monday 8th November, 2021 Estimate
Q3 2021 CTI Biopharma Corp Earnings Release
Tuesday 15th March, 2022 Estimate
Q4 2021 CTI Biopharma Corp Earnings Release
Frequently Asked Questions for CTI Biopharma
What is the CTI Biopharma share price?

As of 24/09/21, shares in CTI Biopharma are trading at $3.04, giving the company a market capitalisation of £207.5m. This share price information is delayed by 15 minutes.

How has the CTI Biopharma share price performed this year?

Shares in CTI Biopharma are currently trading at $3.04 and the price has moved by 0.190k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CTI Biopharma price has moved by 0.115k% over the past year.

What are the analyst and broker recommendations for CTI Biopharma?

Of the analysts with advisory recommendations for CTI Biopharma, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for CTI Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will CTI Biopharma next release its financial results?

CTI Biopharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the CTI Biopharma dividend yield?

CTI Biopharma does not currently pay a dividend.

Does CTI Biopharma pay a dividend?

CTI Biopharma does not currently pay a dividend.

When does CTI Biopharma next pay dividends?

CTI Biopharma does not currently pay a dividend.

How do I buy CTI Biopharma shares?

To buy shares in CTI Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CTI Biopharma?

Shares in CTI Biopharma are currently trading at $3.04, giving the company a market capitalisation of £207.5m.

Where are CTI Biopharma shares listed? Where are CTI Biopharma shares listed?

Here are the trading details for CTI Biopharma:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: CTIC
What kind of share is CTI Biopharma?

Based on an overall assessment of its quality, value and momentum, CTI Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CTI Biopharma share price forecast 2021?

Shares in CTI Biopharma are currently priced at $3.04. At that level they are trading at 0.139% discount to the analyst consensus target price of 0.00.

Analysts covering CTI Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -0.865 for the next financial year.

How can I tell whether the CTI Biopharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CTI Biopharma. Over the past six months, the relative strength of its shares against the market has been -1.24%. At the current price of $3.04, shares in CTI Biopharma are trading at 7.54% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CTI Biopharma PE Ratio?

We were not able to find PE ratio data for CTI Biopharma.

Who are the key directors of CTI Biopharma?

CTI Biopharma's management team is headed by:

Bruce Seeley - COO
Matthew Perry - NID
Michael Metzger - NID
Adam Craig - PRE
David Parkinson - NID
Laurent Fischer - NEC
David Kirske - CFO
Diane Parks - DRC
Who are the major shareholders of CTI Biopharma?

Here are the top five shareholders of CTI Biopharma based on the size of their shareholding:

BVF Partners L.P. Hedge Fund
Percentage owned: 9.57% (8.93m shares)
Stonepine Capital Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 8.18% (7.63m shares)
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 8.06% (7.52m shares)
New Enterprise Associates (NEA) Venture Capital
Percentage owned: 7.65% (7.14m shares)
Altium Capital Management LP Investment Advisor/Hedge Fund
Percentage owned: 3.94% (3.68m shares)
Similar to CTIC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.